EP3668520A4 - Vaccins à arnm modifiés codant pour des glycoprotéines du virus de l'herpès simplex et leurs utilisations - Google Patents

Vaccins à arnm modifiés codant pour des glycoprotéines du virus de l'herpès simplex et leurs utilisations Download PDF

Info

Publication number
EP3668520A4
EP3668520A4 EP18846061.2A EP18846061A EP3668520A4 EP 3668520 A4 EP3668520 A4 EP 3668520A4 EP 18846061 A EP18846061 A EP 18846061A EP 3668520 A4 EP3668520 A4 EP 3668520A4
Authority
EP
European Patent Office
Prior art keywords
herpes simplex
simplex virus
modified mrna
mrna vaccines
vaccines encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18846061.2A
Other languages
German (de)
English (en)
Other versions
EP3668520A1 (fr
Inventor
Harvey Friedman
Drew Weissman
Sita Awasthi
Gary Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Priority to EP23169155.1A priority Critical patent/EP4242223A3/fr
Publication of EP3668520A1 publication Critical patent/EP3668520A1/fr
Publication of EP3668520A4 publication Critical patent/EP3668520A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18846061.2A 2017-08-17 2018-08-17 Vaccins à arnm modifiés codant pour des glycoprotéines du virus de l'herpès simplex et leurs utilisations Pending EP3668520A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP23169155.1A EP4242223A3 (fr) 2017-08-17 2018-08-17 Vaccins à arnm modifiés codant pour des glycoprotéines du virus de l'herpès simplex et leurs utilisations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762546648P 2017-08-17 2017-08-17
US201862701019P 2018-07-20 2018-07-20
PCT/IB2018/056210 WO2019035066A1 (fr) 2017-08-17 2018-08-17 Vaccins à arnm modifiés codant pour des glycoprotéines du virus de l'herpès simplex et leurs utilisations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP23169155.1A Division EP4242223A3 (fr) 2017-08-17 2018-08-17 Vaccins à arnm modifiés codant pour des glycoprotéines du virus de l'herpès simplex et leurs utilisations

Publications (2)

Publication Number Publication Date
EP3668520A1 EP3668520A1 (fr) 2020-06-24
EP3668520A4 true EP3668520A4 (fr) 2021-05-12

Family

ID=65362983

Family Applications (2)

Application Number Title Priority Date Filing Date
EP18846061.2A Pending EP3668520A4 (fr) 2017-08-17 2018-08-17 Vaccins à arnm modifiés codant pour des glycoprotéines du virus de l'herpès simplex et leurs utilisations
EP23169155.1A Pending EP4242223A3 (fr) 2017-08-17 2018-08-17 Vaccins à arnm modifiés codant pour des glycoprotéines du virus de l'herpès simplex et leurs utilisations

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP23169155.1A Pending EP4242223A3 (fr) 2017-08-17 2018-08-17 Vaccins à arnm modifiés codant pour des glycoprotéines du virus de l'herpès simplex et leurs utilisations

Country Status (7)

Country Link
US (3) US11141478B2 (fr)
EP (2) EP3668520A4 (fr)
JP (2) JP7386535B2 (fr)
CN (1) CN111246854A (fr)
AU (2) AU2018316811B2 (fr)
CA (1) CA3073161A1 (fr)
WO (1) WO2019035066A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200054737A1 (en) * 2017-04-26 2020-02-20 Modema TX, Inc. Herpes simplex virus vaccine
EP3668520A4 (fr) 2017-08-17 2021-05-12 The Trustees Of The University Of Pennsylvania Vaccins à arnm modifiés codant pour des glycoprotéines du virus de l'herpès simplex et leurs utilisations
CN111568856B (zh) * 2020-06-24 2021-07-06 珠海舒桐医疗科技有限公司 一种阴道凝胶制剂及其制备方法
US20230256090A1 (en) * 2020-06-29 2023-08-17 Glaxosmithkline Biologicals Sa Adjuvants
AU2021356220A1 (en) 2020-10-08 2023-06-15 Virothera Limited Vaccine compositions
US20240091380A1 (en) 2021-02-01 2024-03-21 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
WO2022189634A1 (fr) * 2021-03-11 2022-09-15 Redbiotec Ag Compositions vaccinales et procédés de traitement du vhs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070623A1 (fr) * 2015-10-22 2017-04-27 Modernatx, Inc. Vaccin contre le virus de l'herpès simplex
WO2017070616A2 (fr) * 2015-10-22 2017-04-27 Modernatx, Inc. Vaccins contre les maladies sexuellement transmissibles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026204A1 (fr) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate
DK2578685T3 (da) 2005-08-23 2019-06-03 Univ Pennsylvania Rna indeholende modificerede nukleosider og fremgangsmåder til anvendelse deraf
WO2008011609A2 (fr) * 2006-07-20 2008-01-24 Vical Incorporated Compositions et méthodes de vaccination contre le hsv-2
US20130028925A1 (en) 2006-12-28 2013-01-31 Harvey Friedman Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2011140627A1 (fr) 2009-11-04 2011-11-17 The University Of British Columbia Particules lipidiques contenant des acides nucléiques et procédés associés
US9192661B2 (en) * 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US9770463B2 (en) * 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
AU2014362234B2 (en) * 2013-12-11 2019-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Human herpesvirus trimeric glycoprotein B, protein complexes comprising trimeric gB and their use as vaccines
MY186389A (en) * 2014-05-13 2021-07-22 Univ Pennsylvania Compositions comprising aav expressing dual antibody constructs and uses thereof
US20170224808A1 (en) * 2014-10-01 2017-08-10 Admedus Vaccines Pty Ltd Therapeutic compositiojns and methods for inducing an immune response to herpes simplex virus type 2 (hsv-2)
JP2018526321A (ja) 2015-04-27 2018-09-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ
US10758694B2 (en) 2015-07-09 2020-09-01 Hoyt Medical LLC Systems and methods for treating an airway using a tapered adapter device
AU2017350488B2 (en) * 2016-10-26 2022-06-23 Acuitas Therapeutics Inc. Lipid nanoparticle mRNA vaccines
US20200054737A1 (en) 2017-04-26 2020-02-20 Modema TX, Inc. Herpes simplex virus vaccine
EP3668520A4 (fr) 2017-08-17 2021-05-12 The Trustees Of The University Of Pennsylvania Vaccins à arnm modifiés codant pour des glycoprotéines du virus de l'herpès simplex et leurs utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070623A1 (fr) * 2015-10-22 2017-04-27 Modernatx, Inc. Vaccin contre le virus de l'herpès simplex
WO2017070616A2 (fr) * 2015-10-22 2017-04-27 Modernatx, Inc. Vaccins contre les maladies sexuellement transmissibles

Also Published As

Publication number Publication date
EP4242223A2 (fr) 2023-09-13
JP7386535B2 (ja) 2023-11-27
EP3668520A1 (fr) 2020-06-24
CA3073161A1 (fr) 2019-02-21
AU2018316811A1 (en) 2020-03-12
CN111246854A (zh) 2020-06-05
AU2023248194A1 (en) 2023-11-02
US20240024463A1 (en) 2024-01-25
JP2020531465A (ja) 2020-11-05
EP4242223A3 (fr) 2024-03-13
US20200276300A1 (en) 2020-09-03
US11141478B2 (en) 2021-10-12
AU2018316811B2 (en) 2023-07-13
JP2023153423A (ja) 2023-10-17
US11793872B2 (en) 2023-10-24
US20210386853A1 (en) 2021-12-16
WO2019035066A1 (fr) 2019-02-21

Similar Documents

Publication Publication Date Title
EP3641810A4 (fr) Vaccin contre le virus de l'herpès simplex
EP3668520A4 (fr) Vaccins à arnm modifiés codant pour des glycoprotéines du virus de l'herpès simplex et leurs utilisations
HK1254293A1 (zh) 一種重組單純皰疹病毒及其用途
EP3365009A4 (fr) Vaccin contre le virus de l'herpès simplex
SG11202011587PA (en) Messenger rna vaccines and uses thereof
EP3490583A4 (fr) Vecteurs de virus de l'herpès simplex oncolytique exprimant des molécules stimulatrices du système immunitaire
EP3402500A4 (fr) Polythérapie à base d'un virus oncolytique et d'un inhibiteur de point de contrôle
EP3367942A4 (fr) Systèmes d'administration d'énergie et utilisations associées
EP3658165A4 (fr) Vecteurs viraux oncolytiques et leurs utilisations
EP3640327A4 (fr) Virus de l'herpès simplex recombinant, sa méthode de préparation et son application
EP3244932A4 (fr) Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn
EP3285594A4 (fr) Systèmes d'administration et procédés de préparation de ceux-ci
EP3468618A4 (fr) Système de libération viral non-intégratif et méthodes associées
EP3419660A4 (fr) Nouveaux vaccins contre le virus zika
EP3577132A4 (fr) Thérapie à base de virus oncolytique
EP3307894A4 (fr) Systèmes d'administration viraux non intégratifs et procédés d'utilisation associés
EP3113801A4 (fr) Vecteurs de vaccin du virus de l'herpès simplex 2 (vhs -2) de recombinaison(hsv -2)
IL288233A (en) Modified viral particles and their use
EP3334833A4 (fr) Vaccins du virus de l'herpès de dinde recombinant et utilisations de celui-ci
ZA202004538B (en) Influenza virus vaccines and uses thereof
EP3604548A4 (fr) Système de vaccin contre virus oncolytique programmable et son application
GB201504251D0 (en) Oncolytic herpes simplex virus infected cells
EP3856895A4 (fr) Vaccins autologues bihapténisés et leurs utilisations
EP3270958A4 (fr) Protéines de fusion comprenant des glycoprotéines de surface d'alpha virus et un antigène associé à une tumeur, et procédés associés
EP3362929A4 (fr) Néoépitopes viraux et utilisations de ces derniers

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200227

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40032877

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20210414

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7088 20060101AFI20210408BHEP

Ipc: A61K 31/7115 20060101ALI20210408BHEP

Ipc: A61K 38/16 20060101ALI20210408BHEP

Ipc: A61K 39/12 20060101ALI20210408BHEP

Ipc: A61K 39/245 20060101ALI20210408BHEP

Ipc: C07K 14/035 20060101ALI20210408BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230313

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524